海翔药业：公司严格遵守证监会、深交所相关法律法规规定履行信息披露义务

Core Viewpoint - Haishang Pharmaceutical (002099) emphasizes its commitment to comply with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding information disclosure [1] Group 1 - The company responded to investor inquiries on October 17, indicating adherence to legal and regulatory obligations [1] - Investors are encouraged to refer to the company's periodic reports and announcements for specific information [1]